Follow POL on Twitter With their customary precision, Beck & Herrmann summarize the state of play, which is not as favorable toward the plaintiff's side as the law firms on that side must have hoped it would be at this point. "Plaintiffs' real gripe is not with promotion of off-label use but with the legality of off-label use itself. But they lost that battle in Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341, 350-51 & n.5 (2001)."
Off-label pharmaceutical promotion suits
Related Entries:
- Greg Conko: Can brand makers be sued for generic drug injuries?
- Greg Conko discusses the FDA's ban on off-label promotion
- Around the web, June 13
- Second Circuit rebukes Weinstein's handling of Zyprexa class action
- A $500 million damage award hardly makes news anymore
- Philadelphia Freedom? Another Round in the Prempro Wars
- Paxil Verdict In: Big Loss for GlaxoSmithKline
- Beck & Herrmann on Allergan suit for the right to promote off-label
- Botox Maker Asks Court: Do We Have A Right to Tell The Truth?
- Big Paxil Test Case Begins in Philadelphia
- "Did the Avandia scare hurt patients?"
- New York Assembly bill could open pharmaceutical litigation floodgates
- Off-label prescribing of drugs
- Copland and Howard: a proposal for drug-injury administrative compensation
- Conte v. Wyeth will stand
 |
| Isaac Gorodetski Project Manager, Center for Legal Policy at the Manhattan Institute igorodetski@manhattan-institute.org |
 |
| Laura Eyi Press Officer, Manhattan Institute leyi@manhattan-institute.org |
